← All stocks

Intellia Therapeutics, Inc.

NTLA Scheduled selling only

CIK 0001652130 #2130 in the set updated 18 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$286.82K

$286.82K on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 2 sales

Net

−$286.82K

$0.00 against sales at will

By person

16 insiders · 2 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

LEONARD JOHN M

President and CEO

—

$286.82K (2) scheduled

−$286.82K

1,147,064

0.8186%

$14.91M

+19.5%

Cohen Fred E

Director

—

216,653

0.1546%

$2.82M

+338.1%

BASTA JAMES

EVP, General Counsel

—

156,794

0.1119%

$2.04M

+70.5%

Dulac Edward J III

EVP, Chief Financial Officer

—

148,175

0.1057%

$1.93M

+123.4%

CHASE WILLIAM J

Director

—

143,893

0.1027%

$1.87M

+439.1%

Schultes Birgit C

EVP, Chief Scientific Officer

—

137,733

0.0983%

$1.79M

+98.3%

Lebwohl David

EVP, Chief Medical Officer

—

131,192

0.0936%

$1.71M

+36.2%

Clark Eliana

EVP, Chief Technical Officer

—

93,864

0.0670%

$1.22M

+26.3%

Sepp-Lorenzino Laura

EVP, Chief Scientific Officer

—

77,388

0.0552%

$1.01M

−6.6%

Dube Michael P

VP, Chief Accounting Officer

—

66,886

0.0477%

$869.52K

+36.4%

Hicks Derek

EVP, Chief Business Officer

—

59,878

0.0427%

$778.41K

−9.8%

Keresty Georgia

Director

—

41,083

0.0293%

$534.08K

+72.0%

Bhanji Muna

Director

—

36,403

0.0260%

$473.24K

+84.5%

Verwiel Frank

Director

—

35,148

0.0251%

$456.92K

+95.8%

GOODMAN JESSE

Director

—

33,559

0.0239%

$436.27K

+72.5%

Goff Brian

Director

—

32,609

0.0233%

$423.92K

+111.6%

Individual transactions

Insider

Date

Role

Action

Price

Amount

LEONARD JOHN M

21 Aug 2026

President and CEO

Sold on a plan

2,785

$13.00

$36.21K

LEONARD JOHN M

20 Aug 2026

President and CEO

Sold on a plan

19,890

$12.60

$250.61K

Show all 2 transactions →

What was left out

Form 4 filings counted 1

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 2

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 0

History held since 5 Jan 2017